#1 Clinical Trials Search in Europe

Dorzolamide Hydrochloride

This article summarizes several clinical trials investigating the use of Dorzolamide Hydrochloride, often in combination with other medications, for treating glaucoma and ocular hypertension. These studies aim to evaluate the efficacy, safety, and tolerability of Dorzolamide Hydrochloride in various formulations and patient populations, including adults and children with different types of glaucoma.

Table of Contents

What is Dorzolamide Hydrochloride?

Dorzolamide Hydrochloride is a medication primarily used to treat eye conditions, particularly glaucoma and ocular hypertension (high pressure in the eye). It belongs to a class of drugs called carbonic anhydrase inhibitors[1]. This medication is often referred to by its brand names, which include Trusopt and Cosopt (when combined with another drug called timolol)[2].

Conditions Treated

Dorzolamide Hydrochloride is used to treat several eye conditions, including:

  • Open-Angle Glaucoma: A condition where the eye’s drainage channels become clogged over time, leading to increased eye pressure[3]
  • Ocular Hypertension: High pressure within the eye without any detectable changes in vision or damage to the eye structure[2]
  • Cystoid Macular Edema: A condition where fluid accumulates in the central part of the retina (macula), causing swelling[4]
  • Pediatric Glaucoma: Glaucoma that occurs in children[5]

How Dorzolamide Works

Dorzolamide Hydrochloride works by reducing the production of fluid inside the eye. It does this by inhibiting an enzyme called carbonic anhydrase. By decreasing fluid production, the medication helps lower the pressure inside the eye, which is crucial in managing conditions like glaucoma[1].

In some cases, Dorzolamide may also help improve blood flow to the eye, which can be beneficial for certain eye conditions[6].

Administration and Dosage

Dorzolamide Hydrochloride is typically administered as eye drops. The usual dosage is one drop in the affected eye(s) three times a day. However, when used in combination with other eye medications, the frequency may be reduced to twice daily[2]. It’s important to follow your doctor’s instructions carefully and not to change the dosage without consulting them first.

Combination Therapies

Dorzolamide is often used in combination with other eye medications to enhance its effectiveness. Common combinations include:

  • Dorzolamide + Timolol: This combination, often sold under the brand name Cosopt, is frequently used to treat glaucoma and ocular hypertension[2]
  • Dorzolamide + Latanoprost: This combination has been studied for use in pediatric glaucoma[5]
  • Dorzolamide + Timolol + Brimonidine + Bimatoprost: A quadruple combination therapy being studied for its effectiveness in lowering eye pressure[7]

Current Clinical Trials

Several clinical trials are ongoing to further explore the benefits of Dorzolamide Hydrochloride:

  • A study investigating its use in combination with a topical carbonic anhydrase inhibitor to improve central visual function[1]
  • Research on its effectiveness when delivered through drug-eluting contact lenses[8]
  • A trial examining its impact on autoregulation (the eye’s ability to maintain stable blood flow) in glaucoma patients[6]
  • An investigation into its potential as an adjuvant therapy after focal photocoagulation in diabetic macular edema[9]

Potential Side Effects

While Dorzolamide Hydrochloride is generally well-tolerated, it may cause some side effects. Common side effects include:

  • Eye irritation or discomfort
  • Blurred vision
  • Bitter taste in the mouth
  • Allergic reactions (in rare cases)

Some studies are specifically looking at the impact of Dorzolamide on dry eye symptoms in patients with glaucoma[2]. If you experience any persistent or severe side effects, it’s important to contact your healthcare provider immediately.

Study Focus Key Findings Patient Population
Dorzolamide/Timolol combination vs. monotherapy Evaluated efficacy in reducing intraocular pressure Adults with open-angle glaucoma or ocular hypertension
Drug-eluting contact lenses Investigated novel delivery method for Dorzolamide and Timolol Patients with glaucoma
Preservative-free Dorzolamide/Timolol Assessed tolerability in patients with dry eyes Open-angle glaucoma or ocular hypertension patients with dry eyes
Dorzolamide in pediatric glaucoma Evaluated efficacy and safety in children Pediatric patients with glaucoma refractory to surgical procedures
Impact on ocular blood flow Studied effects on retrobulbar vascular resistance Primary open-angle and normal tension glaucoma patients

FAQ

  • What is Dorzolamide Hydrochloride? Dorzolamide Hydrochloride is a medication used to treat glaucoma and ocular hypertension. It belongs to a class of drugs called carbonic anhydrase inhibitors, which work by decreasing the production of fluid in the eye, thereby lowering intraocular pressure.
  • How is Dorzolamide Hydrochloride typically administered? Dorzolamide Hydrochloride is usually administered as eye drops. In many clinical trials, it is used in combination with other medications, such as timolol, in a fixed-dose combination eye drop solution.
  • What are the main conditions being studied with Dorzolamide Hydrochloride? The main conditions being studied are open-angle glaucoma, ocular hypertension, and in some cases, childhood glaucoma. These conditions are characterized by increased pressure within the eye, which can lead to vision loss if left untreated.
  • Are there any innovative delivery methods being tested for Dorzolamide Hydrochloride? Yes, one study is exploring the use of drug-eluting contact lenses loaded with Dorzolamide Hydrochloride and timolol maleate. This method aims to improve drug delivery and patient compliance compared to traditional eye drops.
  • What are some of the outcomes being measured in these clinical trials? Common outcomes include changes in intraocular pressure, visual field function, patient satisfaction, tolerability, and safety. Some studies also look at the effect on macular pigment optical density and contrast sensitivity.

Ongoing Clinical Trials on Dorzolamide Hydrochloride

  • Study on the Safety and Effectiveness of AGTC-501 for Men with X-linked Retinitis Pigmentosa

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Glaucoma Treatment: Comparing Brimonidine, Pilocarpine Nitrate, and Brinzolamide in Patients with Newly Diagnosed Open-Angle Glaucoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

Glossary

  • Intraocular Pressure (IOP): The fluid pressure inside the eye. Elevated IOP is a major risk factor for glaucoma and can lead to damage of the optic nerve.
  • Open-Angle Glaucoma: The most common type of glaucoma, where the angle between the iris and cornea remains open, but the eye's drainage canals become clogged over time.
  • Ocular Hypertension: A condition where the pressure inside the eye (intraocular pressure) is higher than normal, but no signs of glaucoma are present.
  • Carbonic Anhydrase Inhibitor: A type of medication that reduces the production of fluid inside the eye, thereby lowering intraocular pressure.
  • Macular Pigment Optical Density: A measure of the amount of protective pigments in the macula, the central part of the retina responsible for detailed vision.
  • Optical Coherence Tomography (OCT): A non-invasive imaging test that uses light waves to take cross-section pictures of the retina.
  • Visual Field: The entire area that can be seen when the eye is focused on a central point. Visual field tests are used to detect blind spots and other visual deficits.
  • Prostaglandin Analogue: A type of medication used to treat glaucoma by increasing the outflow of fluid from the eye, thus lowering intraocular pressure.
  • Fixed-Dose Combination: A medication that includes two or more active ingredients combined in a single dosage form.
  • Drug-Eluting Contact Lens: A contact lens designed to slowly release medication directly onto the surface of the eye over an extended period.

References

  1. https://clinicaltrials.gov/study/NCT04676126
  2. https://clinicaltrials.gov/study/NCT00545064
  3. https://clinicaltrials.gov/study/NCT00449956
  4. https://clinicaltrials.gov/study/NCT00716586
  5. https://clinicaltrials.gov/study/NCT01527682
  6. https://clinicaltrials.gov/study/NCT02053298
  7. https://clinicaltrials.gov/study/NCT06369077
  8. https://clinicaltrials.gov/study/NCT02852057
  9. https://clinicaltrials.gov/study/NCT02227745